Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines
International Journal of Hematology · 2026
DOI: 10.1007/s12185-026-04221-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Hematology, 2026. Verfasst von Naoko Ida und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Matsuoka, Eiheiji, Fukui, 910-1193, Japan. idan@u-fukui.ac.jp. Hauptthemen laut MEDLINE: Inotuzumab Ozogamicin, Drug Resistance, Neoplasm, DNA Repair, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fukui.
Abstract (Originalsprache)
Inotuzumab ozogamicin (IO), an anti-CD22 antibody conjugated with calicheamicin, is highly effective against relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, acquired resistance limits the long-term efficacy of IO. To elucidate the underlying mechanisms of IO resistance and explore strategies to overcome it, six IO-resistant B-ALL sublines were newly established. Although CD22 expression was preserved in all resistant sublines, more than 80-fold increases in 50% inhibitory concentration (IC50) were observed, accompanied by acquired resistance to IO-induced apoptosis. Microarray analysis revealed upregulation of ABCB1, which was further confirmed by overexpression of the encoded protein, the drug efflux pump P-glycoprotein (P-gp). P-gp inhibition restored IO sensitivity by inhibiting calicheamicin efflux, a key resistance mechanism. Concurrently, poly (ADP-ribose) polymerase (PARP) inhibition of DNA damage repair enhanced IO cytotoxicity. Notably, in the triplet combination of IO with P-gp and PARP inhibitors, PARP inhibition of the repair of DNA damage caused by calicheamicin accumulation following P-gp inhibition markedly enhanced the antitumor effects of IO. This approach may offer a novel and effective therapeutic strategy for IO-resistant B-ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Matsuoka, Eiheiji, Fukui, 910-1193, Japan. idan@u-fukui.ac.jp.
- Department of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Matsuoka, Eiheiji, Fukui, 910-1193, Japan.
- Department of Diabetes, Endocrinology, and Hematology, DMU Saitama Medical Center, 2-1-50 Minami-Koshigaya, Koshigaya-Shi, Saitama, 343-8555, Japan.
- Department of Blood Transfusion, University of Fukui Hospital, 23-3, Shimoaizuki, Matsuoka, Eiheiji, Fukui, 910-1193, Japan.
Förderung
- University of Fukui
Zitieren
APA
Ida, N., Okura, M., Tanaka, S., Hosono, N., & Yamauchi, T. (2026). Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines. International Journal of Hematology. https://doi.org/10.1007/s12185-026-04221-2
Vancouver
Ida N, Okura M, Tanaka S, Hosono N, Yamauchi T. Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines. International Journal of Hematology. 2026. doi:10.1007/s12185-026-04221-2
BibTeX
@article{Ida2026,
author = {Ida, Naoko and Okura, Miyuki and Tanaka, Saki and Hosono, Naoko and Yamauchi, Takahiro},
title = {Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines},
journal = {International Journal of Hematology},
year = {2026},
doi = {10.1007/s12185-026-04221-2}
}
EUVIMED